findmyKOL

Peter Merkel, MD, MPH

Enriched profile

Chief, Division of Rheumatology, Hospital of the University of Pennsylvania; Professor of Medicine (Rheumatology) · University of Pennsylvania

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Radnor, PA · Northeast · United StatesSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2011–2026Why? →

Peter Merkel is Chief, Division of Rheumatology, Hospital of the University of Pennsylvania; Professor of Medicine (Rheumatology) at University of Pennsylvania. ClinicalTrials.gov lists 29 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 15 Oct 2026

Peter A. Merkel, MD, MPH, is Chief, Division of Rheumatology, Hospital of the University of Pennsylvania. The public record shows 32 publications with 1,533 citations (h-index 13), centered on Rheumatology/Immunology. It also documents an investigator role on 29 registered clinical trials, industry payments reported by 24 companies, 13 NIH-funded awards (2011–2026).

  • Top research focus: Rheumatology/Immunology
  • 29 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 24 companies

Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Vasculitis22 trialsGranulomatosis with Polyangiitis21 trialsGranuloma21 trialsMicroscopic Polyangiitis16 trialsArteritis15 trialsTakayasu Arteritis12 trialsPolyarteritis Nodosa11 trialsGiant Cell Arteritis11 trialsChurg-Strauss Syndrome8 trialsBehcet Syndrome6 trialsPurpura6 trialsVasculitis, Central Nervous System6 trialsAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis3 trialsST Elevation Myocardial Infarction3 trialsUrticaria3 trialsSystemic Vasculitis3 trialsIgA Vasculitis3 trialsAortitis2 trialsSkin Diseases, Vascular1 trialPolychondritis, Relapsing1 trial

Research focus

OpenAlex concept fingerprint
Rheumatology/Immunology

Drugs & molecules

across trials, industry payments and publications
Fasenrageneric · BenralizumabClinical trials—Industry payments25Publications—Tavneosgeneric · AvacopanClinical trials—Industry payments23Publications—Viltepsogeneric · ViltolarsenClinical trials—Industry payments9Publications—Ofevgeneric · NintedanibClinical trials—Industry payments7Publications—Vyvgartgeneric · Efgartigimod alfaClinical trials—Industry payments4Publications—Kevzarageneric · SarilumabClinical trials—Industry payments3Publications—Actemrageneric · TocilizumabClinical trials—Industry payments2Publications—Beovugeneric · BrolucizumabClinical trials—Industry payments2Publications—Abecmageneric · Idecabtagene vicleucelClinical trials—Industry payments1Publications—Blincytogeneric · BlinatumomabClinical trials—Industry payments1Publications—Cosentyxgeneric · SecukinumabClinical trials—Industry payments1Publications—Nucalageneric · MepolizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments27Amgen Inc.Clinical trials—Industry payments26AstraZeneca UK LimitedClinical trials—Industry payments19University of PennsylvaniaClinical trials18Industry payments—NS Pharma, Inc.Clinical trials—Industry payments15AstraZeneca Pharmaceuticals LPClinical trials—Industry payments13E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments10Otsuka Pharmaceutical Development & Commercialization, Inc.Clinical trials—Industry payments9Boehringer Ingelheim International GmbHClinical trials—Industry payments8Argenx Us, Inc.Clinical trials—Industry payments6University of South FloridaClinical trials6Industry payments—AstraZeneca ABClinical trials—Industry payments5Celgene CorporationClinical trials—Industry payments5Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments3Genzyme CorporationClinical trials—Industry payments3Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments3Abbvie Inc.Clinical trials—Industry payments2Chugai Pharmaceutical Co., Ltd.Clinical trials—Industry payments2InflaRx GmbHClinical trials2Industry payments—Novartis Pharma AGClinical trials—Industry payments2Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2Cambridge University Hospitals NHS Foundation TrustClinical trials1Industry payments—Eli Lilly and CompanyClinical trials—Industry payments1EMD Serono, Inc.Clinical trials—Industry payments1GlaxoSmithKline, LLC.Clinical trials—Industry payments1Janssen Biotech, Inc.Clinical trials—Industry payments1Jubilant Therapeutics IncClinical trials—Industry payments1Novartis Pharmaceuticals CorporationClinical trials—Industry payments1Peter MerkelClinical trials1Industry payments—University of OxfordClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
29clinical trials

Investigator role on registered studies.

View trials ↓
24companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
13NIH grants · 2011–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 15 Oct 2026

Listed as an investigator on 29 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 15 Oct 2026

24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    100%
    Corticosteroid100%
    Prednisone100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 15 Oct 2026

13 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 15 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/peter-merkel-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • ResearchGate

    researchgate.net/scientific-contributions/Peter-A-Merkel-38922776

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/DrPeterMerkel

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/ACRheum/status/1715391446134509942

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 15 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.P.H.

    Harvard School of Public Health

    1995
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • Board Certified

    Rheumatology

    1994
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
  • M.D.

    Yale University School of Medicine

    1988
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
  • B.A.

    Wesleyan University

    1983
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗

Editorial & leadership roles

journal and society appointments
  • Principal Investigator

    NIH-sponsored Vasculitis Clinical Research Consortium (VCRC)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • Principal Investigator

    Vasculitis Patient-Powered Research Network (VPPRN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vasculitisfoundation.org ↗
  • Chair

    OMERACT Vasculitis Working Group

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cceb.med.upenn.edu ↗
  • Founding member

    NIH Rare Diseases Clinical Research Network (RDCRN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cceb.med.upenn.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
  • Member

    Scientific Advisory Board, Kyverna Therapeutics

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kyvernatx.com ↗
  • Director

    Penn Vasculitis Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.upenn.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.